Adipotide (FTPP): The Fat-Targeting Peptide Explained (2026 Guide)

Adipotide — formally known as FTPP (fat-targeted proapoptotic peptide) — is one of the most unusual experimental compounds in modern peptide research. Unlike thermogenics that raise metabolism or GLP-1 agonists like Semaglutide that suppress appetite, Adipotide works via a completely different mechanism: it targets and destroys the blood supply feeding white adipose tissue, causing localized fat cell death through apoptosis.

Preclinical research in obese monkeys produced dramatic results that captured significant scientific attention. But the compound's development was halted due to serious kidney toxicity concerns — making it one of the most fascinating and cautionary stories in peptide research.

This guide covers the full science behind Adipotide: what it is, how it works, what the animal research actually showed, the risks identified, and where the research currently stands.

How Adipotide Works: The Targeted Apoptosis Mechanism

Adipotide is a bipartite peptidomimetic — meaning it consists of two functional peptide segments joined by a glycine linker. Understanding each segment explains the compound's remarkable selectivity.

Segment 1: CKGGRAKDC — This homing sequence binds specifically to prohibitin, a protein expressed on the inner surface of blood vessels (endothelium) that supply white adipose tissue. Critically, prohibitin is not significantly expressed on the vasculature feeding other tissue types under normal conditions, giving the peptide its targeting specificity.

Segment 2: D(KLAKLAK)₂ — Once the homing sequence has docked onto prohibitin-expressing endothelial cells, this proapoptotic sequence disrupts mitochondrial membranes, triggering programmed cell death (apoptosis) in those specific endothelial cells.

The net result is a two-step process: the peptide seeks out blood vessels feeding fat depots, then causes those vessels to undergo apoptosis. Without a blood supply, the surrounding white adipose cells are starved of nutrients and oxygen and subsequently die — a process called ischemic apoptosis.

This mechanism has been described in scientific literature as analogous to a precision-guided missile: it does not elevate heart rate, does not modulate appetite centrally, and does not alter systemic metabolism. It acts locally on fat tissue vasculature.

What the Primate Research Actually Showed

The landmark study published in Science Translational Medicine (Barnhart et al., 2011) is the central piece of Adipotide research. Researchers administered Adipotide to obese rhesus monkeys — a primate model considered highly relevant to human obesity physiology.

Body Weight and Fat Loss Results

Over a 28-day treatment period, obese monkeys receiving Adipotide lost an average of approximately 11% of their body weight. Crucially, the researchers used MRI and DEXA imaging to confirm this was predominantly fat mass — with reductions observed in both subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), the latter being the metabolically dangerous fat surrounding internal organs.

Control animals receiving saline showed no significant weight loss over the same period.

Metabolic Improvements Observed

Beyond the fat loss itself, the study documented secondary metabolic improvements in treated animals:

• Improved insulin sensitivity and reduced insulin resistance scores
• Reductions in fasting blood glucose levels
• Improvements in lipid profiles
• Decreased waist-to-hip ratio measurements

These findings suggested that Adipotide's fat-reduction effects translated into broader metabolic benefits — not merely cosmetic changes in body composition.

Kidney Toxicity: The Critical Finding

The same study identified a significant concern: reversible kidney toxicity. Animals treated with Adipotide showed elevated creatinine levels and structural changes in renal tubular cells, consistent with renal tubular injury. Importantly, the researchers reported this toxicity appeared reversible upon cessation of treatment — kidneys recovered over time in monitored animals.

However, the mechanism of this nephrotoxicity was not fully elucidated, and the dose-response relationship raised concerns about the therapeutic window — the margin between an effective dose and a toxic dose.

Adipotide Dosing: What the Research Protocols Used

It is essential to frame all Adipotide dosing data in its proper context: these figures come exclusively from preclinical animal studies. There are no validated human dosing protocols, and no Phase I or Phase II human clinical trial data has been published.

Primate Study Dosing Parameters

In the Barnhart 2011 study, Adipotide was administered via subcutaneous injection. The dose range used was approximately 100 mcg/kg to 1000 mcg/kg, with the primary experimental dose reported at approximately 1000 mcg/kg body weight. The treatment period was 28 consecutive days.

At lower doses (100 mcg/kg range), fat loss effects were attenuated. The kidney toxicity signal was most pronounced at the higher dose ranges used.

Rodent Research Dosing

Earlier rodent studies (mice) used somewhat different weight-adjusted doses. Obese mice treated with Adipotide showed fat mass reductions with shorter treatment windows, though rodent models present significant translational limitations for a compound of this nature.

Administration Route

All published research used subcutaneous (SC) injection as the delivery route. The peptide does not appear to have been investigated via oral administration, which would likely result in degradation before systemic absorption.

Why Adipotide's Clinical Development Was Discontinued

Following the 2011 primate publication, there was considerable scientific and media interest in Adipotide as a potential anti-obesity therapeutic. A small Phase I exploratory trial in prostate cancer patients with obesity was initiated — not primarily as a weight loss study, but as part of an oncology-adjacent program exploring CKGGRAKDC-targeted delivery systems.

However, the development pathway for Adipotide as a standalone anti-obesity drug did not advance to Phase II trials. Several factors contributed:

• Renal safety concerns: The kidney toxicity signal in primates represented a serious barrier to an obesity indication, where a drug would need to be taken by otherwise healthy individuals long-term
• Therapeutic window questions: The margin between effective and nephrotoxic doses required more extensive characterization
• Competitive landscape: The emergence of GLP-1 receptor agonists (like Semaglutide) with robust clinical data created a high bar for any competing obesity compound
• Mechanism complexity: The long-term consequences of vascular apoptosis in adipose tissue — including potential effects on tissue architecture, lymphatics, and regeneration — were not fully characterized

The compound remains an active area of academic research interest, particularly as a model for targeted vascular delivery and as a potential tool in oncology research (prohibitin targeting has implications beyond adipose tissue).

Adipotide vs. Other Fat-Loss Research Peptides

Researchers studying metabolic compounds often encounter Adipotide in the context of comparing mechanisms across different peptide classes. Here is how it differs from other commonly researched compounds:

Adipotide vs. Semaglutide: Semaglutide is a GLP-1 receptor agonist that reduces food intake centrally and slows gastric emptying. It has extensive human trial data and regulatory approval. Adipotide operates peripherally at the tissue level with no central appetite effects — a fundamentally different mechanism with no approved clinical use.

Adipotide vs. BPC-157: BPC-157 is a regenerative/healing peptide with no direct fat-loss mechanism. The two operate in completely different research domains.

Adipotide vs. Ipamorelin / CJC-1295: These growth hormone secretagogues may modestly improve body composition by increasing GH pulsatility and lean mass over time. Their mechanism is systemic and hormonal, not targeted vascular apoptosis.

Adipotide occupies a genuinely unique mechanistic niche — no other well-characterized research peptide uses targeted proapoptotic vascular destruction as its primary mode of action.

Frequently Asked Questions About Adipotide